显示该栏目以下所有产品
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
简易精神状态检查量表第2版（MMSE-2）
简易精神状态检查量表第2版MMSE-2（MMSE-2 Mini-Mental State Examination, 2nd Edition），具有与原始的MMSE相同的标准版，以及简短版和扩展版，它保留了临床实用性和有效性，同时在轻度认知障碍（包括皮质下痴呆）人群中扩展了最初的实用性。
开发者：Marshal F. Folstein医学博士和Susan E.Folstein医学博士
用户手册撰写者：Marshal F. Folstein医学博士；Susan E. Folstein医学博士；Travis White博士；Melissa A. Messer, MHS
目的：筛查认知障碍
格式：纸笔测试
年龄范围：18岁及以上
测试时间：MMSE-2：BV（简短版）为5分钟； MMSE-2：SV（标准版）为10-15分钟； MMSE-2：EV（扩展版）为20分钟
资质代码：S
产品特点：
- 测试管理的灵活性。提供三种不同的版本（简短版、标准版、加强版），可以选择最适合患者需求的版本用于测试。
- 评分简单。表单易于使用且易于评分。
- 便携式的口袋规范指南。用户手册和方便的袖珍规范指南，都提供了T分数转换表、可靠变化分数（在三个统计显著性水平上）和平均原始分数表。
- 等效替代形式。蓝色和红色表格可以在减少练习的情况下重新测试同一个病人。
- 测试管理简单。所有版本都可以由受过测试认知障碍患者培训并熟悉相关测试管理说明的人员进行。不需要特殊设备。
- 临床关联性。项目与日常生活中的功能能力有明显的关系。
- 扩展统合分析。对原MMSE临床指南中使用MMSE的研究的再分析，扩展到包括2001年到2009年间发表的研究成果，并包括效应量。
测试版本：
- MMSE-2：标准版（Standard Version）。在原有的30要点MMSE的结构和评分不变的情况下，对问题项进行了替换，并对若干任务进行了修改，以调整难度水平。由于整体难度和原始评分范围与原来相同，MMSE-2:SV（标准版）评分和MMSE评分具有可比性。
- MMSE-2：简短版（Brief Version）。16要点MMSE-2:BV（简短版）完全由注册、时间定向、地点定向和回忆任务组成，可用于需要快速认知筛选的临床或研究情况，无需刺激物即可测试评估。
- MMSE-2：扩展版（Expanded Version）。90要点MMSE-2:EV（扩展版）对皮质下痴呆和与衰老相关的变化更为敏感；增加了两个新任务（故事记忆和处理速度）。
技术信息：
- 采用1500多人的标准样本建立信度和正常评分范围；对阿尔茨海默症患者和皮质下痴呆症患者的临床样本进行效度检验。
- 为了帮助使用者确定特定原始评分的临床意义，按临床组别列出了每种版本的MMSE-2的敏感性，特异性，正确分类的百分比，广泛的原始评分临界值的阳性预测能力和阴性预测能力。
- 临床样本的内部一致性系数在.66到.79之间。用G系数检验蓝色和红色表格的等效性，这三个版本的G系数均为≥.96。可靠性系数在.94到.99之间。
- MMSE-2的聚合效度，已通过与多项旨在衡量认知功能特定方面的测试量表进行了相关性的检验，其中包括韦氏成人记忆量表第三版（WMS®-III）相关的子测试，波士顿命名测验（Boston Naming Test），连线测验（Trail Making Test）等。
其他语言版本
- MMSE-2的材料已经被翻译成了三个西班牙语版本，供那些生活在欧洲、拉丁美洲和美国的人们使用。这些产品使用当地收集的标准化数据和/或临床患者数据。
- MMSE-2还提供德语、法语、荷兰语、简体中文、俄语、意大利语和印地语版本。
- MMSE-2标准版本的简体中文版，适合说中文的用户。MMSE-2三种版本（标准版，简要版，扩展版）的两种形式的评分表（蓝色和红色）也均已翻译。《管理和评分手册》包含有关测试管理，评分和选择使用的MMSE-2版本的详细信息。
- 非英语版MMSE-2的用户应根据本地收集的标准化数据和/或临床患者数据对MMSE-2评分进行临床解释。MMSE-2原始评分截止范围的临床应用应以MMSE/MMSE-2的科学文献为基础。
套装：
- MMSE-2简易精神状态检查量表第2版，简体中文标准版套装，型号：6880-KT
- MMSE-2简易精神状态检查量表第2版，标准版套装，型号：6682-KT
- MMSE-2简易精神状态检查量表第2版，扩展版套装，型号：6683-KT
简易精神状态检查量表第2版MMSE-2（MMSE-2 Mini-Mental State Examination, 2nd Edition），文献索引（部分）：
- Arch Clin Neuropsychol. 2023 Feb 18;38(2):196-204. doi: 10.1093/arclin/acac093.
- Radiat Oncol J. 2023 Jun;41(2):89-97. doi: 10.3857/roj.2023.00052. Epub 2023 Jun 26.
- Front Aging Neurosci. 2022 Sep 8;14:984708. doi: 10.3389/fnagi.2022.984708. eCollection 2022.
- Front Digit Health. 2022 Dec 21;4:1029810. doi: 10.3389/fdgth.2022.1029810. eCollection 2022.
- Neurol Sci. 2022 Jan;43(1):81-84. doi: 10.1007/s10072-021-05630-3. Epub 2021 Oct 20.
- J Alzheimers Dis. 2022;90(1):305-312. doi: 10.3233/JAD-220567.
- J Geriatr Psychiatry Neurol. 2022 Jul;35(4):555-564. doi: 10.1177/08919887211029383. Epub 2021 Jul 22.
- BMC Geriatr. 2022 Jan 21;22(1):67. doi: 10.1186/s12877-021-02732-7.
- Altern Ther Health Med. 2022 Jan;28(1):26-31.
- Clin Drug Investig. 2022 May;42(5):391-402. doi: 10.1007/s40261-022-01136-8. Epub 2022 Mar 28.
- Dement Neurocogn Disord. 2021 Oct;20(4):41-51. doi: 10.12779/dnd.2021.20.4.41. Epub 2021 Sep 27.
- Int J Environ Res Public Health. 2021 Feb 10;18(4):1694. doi: 10.3390/ijerph18041694.
- PLoS One. 2021 Jul 8;16(7):e0254055.doi: 10.1371/journal.pone.0254055. eCollection 2021.
- Eur J Neurol. 2021 Jan;28(1):132-140.doi: 10.1111/ene.14494. Epub 2020 Sep 27.
- Alzheimer Dis Assoc Disord. 2020 Jul-Sep;34(3):278-281. doi: 10.1097/WAD.0000000000000403.
- Alzheimers Dement (Amst). 2020 Aug 18;12(1):e12081. doi: 10.1002/dad2.12081. eCollection 2020.
- Parkinsons Dis. 2020 Oct 28;2020:8983960. doi: 10.1155/2020/8983960. eCollection 2020.
- J Alzheimers Dis. 2019;67(2):555-570.doi: 10.3233/JAD-180759.
- J Alzheimers Dis. 2019;67(2):555-570. doi: 10.3233/JAD-180759.
- J Alzheimers Dis. 2018;65(3):1029-1039.doi: 10.3233/JAD-171088.
- 请仔细阅读以下本产品重要说明。
本产品重要说明：
- 语言：英文（MMSE-2简体中文标准版除外）
- 计分表格：纸张
- 国际惯例：相应的专业人员购买并使用
- 产品主要参数：MMSE-2（Mini-Mental State Examination 2nd Edition）
- 原装进口，产地美国
- 尊重并维护知识产权，请按以下列表选择购买使用量表类产品，以实现教学、科研等工作的严谨性和信效度
| 套装 | ||
| 6880-KT | 简易精神状态检查量表第2版（MMSE-2），简体中文标准版套装 | 电邮询价 |
| 6682-KT | 简易精神状态检查量表第2版（MMSE-2），标准版套装 | 电邮询价 |
| 6683-KT | 简易精神状态检查量表第2版（MMSE-2），扩展版套装 | 电邮询价 |
| 手册 | ||
| 6881-TM | 简易精神状态检查量表第2版（MMSE-2），简体中文管理和评分手册 | 电邮询价 |
| 6684-TM | 简易精神状态检查量表第2版（MMSE-2），用户手册 | 电邮询价 |
| 6691-TC | 简易精神状态检查量表第2版（MMSE-2），袖珍规范指南 | 电邮询价 |
| 组件 | ||
| 6888-SK | 简易精神状态检查量表第2版（MMSE-2），简体中文处理速度评分模板-蓝色和红色（2个一组） | 电邮询价 |
| 6692-SK | 简易精神状态检查量表第2版（MMSE-2），处理速度评分模板-蓝色和红色（2个一组） | 电邮询价 |
| 量表 | ||
| 6685-RF | 简易精神状态检查量表第2版（MMSE-2），标准版蓝色评分表格（25份/套） | 电邮询价 |
| 6686-RF | 简易精神状态检查量表第2版（MMSE-2），标准版红色评分表格（25份/套） | 电邮询价 |
| 6687-RF | 简易精神状态检查量表第2版（MMSE-2），简短版蓝色评分表格（25份/套） | 电邮询价 |
| 6688-RF | 简易精神状态检查量表第2版（MMSE-2），简短版红色评分表格（25份/套） | 电邮询价 |
| 6689-RF | 简易精神状态检查量表第2版（MMSE-2），扩展版蓝色评分表格（25份/套） | 电邮询价 |
| 6690-RF | 简易精神状态检查量表第2版（MMSE-2），扩展版红色评分表格（25份/套） | 电邮询价 |
| 6882-RF | 简易精神状态检查量表第2版（MMSE-2），简体中文标准版蓝色评分表格（25份/套） | 电邮询价 |
| 6883-RF |
简易精神状态检查量表第2版（MMSE-2），简体中文标准版红色评分表格（25份/套） |
电邮询价 |
| 6884-RF | 简易精神状态检查量表第2版（MMSE-2），简体中文简短版蓝色评分表格（25份/套） | 电邮询价 |
| 6885-RF | 简易精神状态检查量表第2版（MMSE-2），简体中文简短版红色评分表格（25份/套） | 电邮询价 |
| 6886-RF | 简易精神状态检查量表第2版（MMSE-2），简体中文扩展版蓝色评分表格（25份/套） | 电邮询价 |
| 6887-RF | 简易精神状态检查量表第2版（MMSE-2），简体中文扩展版红色评分表格（25份/套） | 电邮询价 |
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
MMSE-2 Mini-Mental State Examination, 2nd Edition Marshal F. Folstein, MD, and Susan E. Folstein, MD; Users Manual by Marshal F. Folstein, MD, Susan E. Folstein, MD, Travis White, PhD, and Melissa A. Messer, MHS Purpose: Screens for cognitive impairment Format: Paper and pencil Age range: 18 years and older Time: 5 minutes for the MMSE-2:BV; 10-15 minutes for the MMSE-2: SV; 20 minutes for the MMSE-2: EV Qualification level: S With a standard version that is equivalent to the original MMSE and brief and expanded forms, the MMSE-2 retains clinical utility and efficiency while expanding the original’s usefulness in populations with milder forms of cognitive impairment, including subcortical dementia. Features and benefits Flexibility of administration. With three different versions available, you can select the version that best fits your patients’ needs. Simplicity of scoring. Forms are user-friendly and easy to score. Portable Pocket Norms Guide. T-score conversion tables, reliable change scores (at three levels of statistical significance), and mean raw score tables are provided in both the User’s Manual and the handy Pocket Norms Guide. Equivalent, alternate forms. Blue and Red forms enable you to retest the same patient with reduced practice effects. Simplicity of administration. All versions may be administered by anyone who has been trained to test individuals with cognitive impairment and who is familiar with the administration instructions. No special equipment is required. Clinical relevance. Items have obvious relationships to functional ability in daily life. Expanded meta-analysis. The meta-analysis of studies using the MMSE that appeared in the original MMSE Clinical Guide has been expanded to incorporate studies published between 2001 and 2009 and includes effect sizes. Test structure MMSE-2: Standard Version. While the structure and scoring of the original 30-point MMSE remain, problematic items were replaced and several tasks were modified to adjust difficulty level. Because the overall difficulty and raw score range remain the same as in the original, MMSE-2:SV scores and MMSE scores are comparable. MMSE-2: Brief Version. Composed entirely of the Registration, Orientation to Time, Orientation to Place, and Recall tasks, the 16-point MMSE-2:BV can be used for clinical or research situations that call for a rapid cognitive screener that requires no stimuli for administration. MMSE-2: Expanded Version. The 90-point MMSE-2:EV is more sensitive to subcortical dementia and to changes associated with aging; it is sufficiently difficult that it does not have a ceiling effect. Two new tasks (Story Memory and Processing Speed) have been added. Technical information A normative sample of more than 1,500 individuals was used to establish reliability and the normal range of scores; a clinical sample of patients with Alzheimer’s disease and patients with subcortical dementia was tested to establish validity. To help you determine the clinical significance of specific raw scores, the sensitivity, specificity, percent correctly classified, positive predictive power, and negative predictive power of a wide range of raw score cutoffs are presented for each version of the MMSE-2 by clinical group. Internal consistency coefficients ranged from .66 to .79 for the clinical sample. Equivalency of the Blue and Red forms was examined using G coefficients, which were ≥ .96 for all three versions. Interrater reliability coefficients ranged from .94 to .99. Convergent validity of the MMSE-2 was examined in terms of its correlations with several tests that purport to measure specific aspects of cognitive functions, including the WMS®-III Digit Span Forward and Digit Span Backward subtests, the Category Naming Test, the Boston Naming Test, and the Trail Making Test. Available in other languages The MMSE-2 materials have been translated into three Spanish versions for those who live in Europe, Latin America, and the United States. These products use locally collected standardization data and/or clinical patient data. The MMSE-2 is also available in German, French, Dutch, Simplified Chinese, Russian, Italian, and Hindi. Call 1.800.331.8378 for more information. Note: In order to use a modified version of the MMSE–2, including a modified format or translation, please download and complete the Permission Request Form.
相关产品
